Oncology

Latest News

Most Popular Articles of 2024 in Evidence-Based Oncology
Most Popular Articles of 2024 in Evidence-Based Oncology

December 23rd 2024

Prior authorization, PBM reform, and payment for patient navigation were topics of the most popular articles in EBO in 2024.

Highlights From ASCO 2024
ICYMI: Highlights From ASCO 2024

December 21st 2024

chemotherapy | Image credit: Penn Medicine
The High Cost of Shortages of Low-Cost Chemotherapy

December 19th 2024

Leukemia diagnosis | Image credit: Vitalii Vodolazskyi - stock.adobe.com
Real-World Treatment Sequences and Cost Analysis of cBTKis in CLL

December 17th 2024

FDA approved stamp in black with a red ribbon across it | Image credit: BHM - stock.adobe.com
Cosibelimab Approved for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

December 16th 2024

Join this panel as they discuss treatment for metastatic NSCLC patients without driver mutations.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Characteristics of Patients With CML Willing to Attempt Treatment-Free Remission
July 12th 2018

Characteristics of Patients With CML Willing to Attempt Treatment-Free Remission

Laura Joszt, MA
Only 34% of patients with chronic myeloid leukemia (CML) in a small study in China were likely to be positive about attempting treatment-free remission.
Study Identifies New Form of Small-Cell Lung Cancer
July 12th 2018

Study Identifies New Form of Small-Cell Lung Cancer

Alison Rodriguez
Researchers have recently discovered a new type of small-cell lung cancer, and the discovery may pave the way for the development of personalized medicine in order to target this newly discovered form of the disease.
FDA Grants Keytruda Priority Review to Treat Most Common Form of Liver Cancer
July 11th 2018

FDA Grants Keytruda Priority Review to Treat Most Common Form of Liver Cancer

Samantha DiGrande
The FDA has granted priority review for Keytruda (pembrolizumab) as a treatment for previously treated patients with advanced hepatocellular carcinoma (HCC).
CLL: Combination Strategies and Unmet Needs
July 11th 2018

CLL: Combination Strategies and Unmet Needs

CLL: Rationale for Ibrutinib and Sequencing
July 11th 2018

CLL: Rationale for Ibrutinib and Sequencing

Initiating Frontline Therapy in CLL
July 11th 2018

Initiating Frontline Therapy in CLL

The Biology and Diagnosis of CLL
July 11th 2018

The Biology and Diagnosis of CLL

Combination Therapy Values and Future Outlook in CLL
July 11th 2018

Combination Therapy Values and Future Outlook in CLL

CLL: Impact of Combination Therapies on Managed Care
July 11th 2018

CLL: Impact of Combination Therapies on Managed Care

Role of Real-World Data and Sequencing in CLL
July 11th 2018

Role of Real-World Data and Sequencing in CLL

CLL: Treatment Pathway Changes and Cost Effectiveness
July 11th 2018

CLL: Treatment Pathway Changes and Cost Effectiveness

Clinical Impact of the RESONATE-2 Trial in CLL
July 11th 2018

Clinical Impact of the RESONATE-2 Trial in CLL

CLL: Managed Care Outlook on Clinical Trial Data
July 11th 2018

CLL: Managed Care Outlook on Clinical Trial Data

Coverage and Clinical Support in CLL Treatment
July 11th 2018

Coverage and Clinical Support in CLL Treatment

Diagnostic Factors and Treatment Changes in CLL
July 11th 2018

Diagnostic Factors and Treatment Changes in CLL

CLL: Addressing Treatment Paradigms and Unmet Needs
July 11th 2018

CLL: Addressing Treatment Paradigms and Unmet Needs

CLL: Unmet Needs and Future Outlook
July 11th 2018

CLL: Unmet Needs and Future Outlook

Rationale for Novel Combinations in CLL
July 11th 2018

Rationale for Novel Combinations in CLL

CLL: Data Impact and Sequencing Approach
July 11th 2018

CLL: Data Impact and Sequencing Approach

Clinical Significance of Upfront Ibrutinib in CLL
July 11th 2018

Clinical Significance of Upfront Ibrutinib in CLL

CLL: When to Initiate Frontline Therapy
July 11th 2018

CLL: When to Initiate Frontline Therapy

Identifying Mutational Status in CLL
July 11th 2018

Identifying Mutational Status in CLL

Diagnosing Chronic Lymphocytic Leukemia
July 11th 2018

Diagnosing Chronic Lymphocytic Leukemia

Dr John Schorge on Neoadjuvant Chemotherapy Treatment in Advanced Ovarian Cancer
July 11th 2018

Dr John Schorge on Neoadjuvant Chemotherapy Treatment in Advanced Ovarian Cancer

John Schorge, MD, associate editor of The Green Journal, and Gynecologic Oncologist at Tufts Medical Center, discusses the findings of his study on neoadjuvant chemotherapy treatment of patients with advanced ovarian cancer.
Site Logo
July 11th 2018

Current Rectal Cancer Treatments Fall Short for Younger Patients With Advanced Disease

Surabhi Dangi-Garimella, PhD
Current standard of care treatment for rectal cancer, which recommends combining surgery with chemotherapy and radiation, fails to prolong survival in patients younger than 50 years of age, according to findings published early online in the journal Cancer.
Patients With Newly Diagnosed MM Taking Twice-Weekly Ixazomib Achieve High ORR
July 10th 2018

Patients With Newly Diagnosed MM Taking Twice-Weekly Ixazomib Achieve High ORR

Laura Joszt, MA
Ixazomib taken twice weekly with lenalidomide and dexamethasone resulted in high overall response rate (ORR) and a durable response among patients with newly diagnosed multiple myeloma (MM).
Site Logo
July 10th 2018

Narrow Networks in Cancer Care: Tough on Patients but Here to Stay

Mary Caffrey
Experts at the National Comprehensive Cancer Network Policy Summit discussed the present challenges of transitioning to alternative payment models at a time when the costs of many cancer therapies are rising.
Experts Suggest Prioritizing Price and Benefit, Allowing Negotiations for Targeted Cancer Drugs
July 8th 2018

Experts Suggest Prioritizing Price and Benefit, Allowing Negotiations for Targeted Cancer Drugs

Alison Rodriguez
Experts recently proposed 3 steps to promote targeted cancer drugs that yield clinical benefits while reducing overall price growth.
Research Highlights Long-Term Survival and Health-Related QoL in Patients With Newly Diagnosed MM
July 6th 2018

Research Highlights Long-Term Survival and Health-Related QoL in Patients With Newly Diagnosed MM

Laura Joszt, MA
Research presented at the 2018 American Society of Clinical Oncology Annual Meeting identified predictors of long-term survival and health-related quality of life (QoL) in patients with newly diagnosed multiple myeloma (MM).
Dr Peter Paul Yu on Progress in the Move Toward Interoperability
July 6th 2018

Dr Peter Paul Yu on Progress in the Move Toward Interoperability

Peter Paul Yu, MD, FASCO, FACP, physician-in-chief, Hartford HealthCare Cancer Center, discusses the shift toward interoperability among electronic health record systems and efforts needed to accelerate this shift.
<1
...
394041424344454647
...
181>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo